Slide 1: Harnessing the advantages of TB-LAMP in India's private healthcare sector
Harnessing the advantages of TB-LAMP in India’s private healthcare sector Dr. Shalabh Malik, MD National Head Microbiology & Molecular Department
Slide 2: Dr. Lal PathLabs
Dr. Lal PathLabs Where Quality, Service, Innovation is a way of life
Slide 3: Undisputable Leaders in Diagnostics
Undisputable Leaders in Diagnostics • One of the largest and most respected diagnostic service provider in the country • Backed by a proven track record of over six decades for strict adherence to international standards and benchmarks • Over 200 state-of-the-art laboratories, over 2600 collection c
Slide 4: Leveraging the advantages
Leveraging the advantages • World-class Quality – Accredited by College of American Pathologists (CAP), National Accreditation Board for Testing and Calibration Laboratories (NABL), ISO 9001: 2008 certification from British Standards Institution (BSI), Centre for Disease Control (CDC), Atlanta, Geor
Slide 5: India is the highest TB burden country
India is the highest TB burden country accounting for more than one-fourth of the global incidence • The estimated TB incidence in India 27 India is 2.7 million % Other countries 20% • In 2018, RNTCP was able to achieve a notification of 2.1 Other 13 HBCs China 16% million 11% • Of the total notific
Slide 6: High Yielding Facts
High Yielding Facts • WHO FIND clinical trials were conducted by FIND across 22 countries • Inclusion of TB-LAMP in WHO Essential Diagnostics List published in July 2018 • Inclusion of TB-LAMP in Global Drug Facility under the Stop TB Partnership program • High sensitivity (94 - 100%) and specificit
Slide 7: TB-LAMP test performed on pulmonary samples March to September 2019
TB-LAMP test performed on pulmonary samples during March to September 2019 400 312 300 Total no 200 Positive 62 % of Positive 19,9 100 0 TB-LAMP TB-LAMP detected additional 10% more positive cases than SSM
Slide 8: Experience at Dr. Lal PathLabs
Experience at Dr. Lal PathLabs • Test has been launched six months ago post 100% accuracy and precision testing • Most economic and fastest molecular test • Possible with minimum sample volume esp. in case of EPTB – 60-100 µL • Economical in terms of capex and consumables
Slide 9: Experience at Dr. Lal PathLabs
Experience at Dr. Lal PathLabs • No heavy infrastructure or biosafety requirements • Amplified DNA in surplus to enable naked eye detection • Have expanded it’s horizon by combining it with multiplex in Biofire panels • Fast adoption due to simplicity and low training requirement • Efficient QC supp
Slide 10: Areas of improvement
Areas of improvement • Does not cover the Govt. approach that all positive TB cases should be tested for their rifampicin status • Difficulties of TB-LAMP to detect MTB in samples with very low MTB content (Ct value 30 to 35) • Increasing awareness for the advantages of TB-LAMP and stronger penetrat
Slide 11: New Test Panels
New Test Panels • Creating new Test panel to include TB-LAMP with Bio Fire • More panels to follow soon
Slide 12: Thank you for your attention
Thank you for your attention J hank you’